Coronavirus vaccine developer CureVac raises $213 million in IPO: source

This post was originally published on this site

The German biotechnology firm sold 13.33 million shares at $16 apiece, the top end of its indicated price range, the source said, requesting anonymity ahead of an initial announcement. The company’s shares are set to trade in New York on Friday.

CureVac did not immediately respond to a request for comment.